![James Scibetta](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
James Scibetta
Direktor/Vorstandsmitglied bei MATINAS BIOPHARMA HOLDINGS, INC.
Vermögen: 106 593 $ am 31.05.2024
Profil
James S.
Scibetta is currently the Chief Executive Officer & Director at Maverick Therapeutics, Inc., ImmuneID, Inc., and an Independent Director at Matinas BioPharma Holdings, Inc. He previously served as Chairman at Nephros, Inc., Director at Labopharm, Inc., Chief Financial Officer at Bioenvision, Inc., and Chief Financial Officer & Executive Vice President at Merrimack Pharmaceuticals, Inc. He was also the President at Pacira Biosciences, Inc. from 2016 to 2017 and an Independent Director at Aquestive Therapeutics, Inc. from 2017 to 2022.
Scibetta received his undergraduate degree from Wake Forest University and his MBA from the University of Michigan.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
18.03.2024 | 649 958 ( 0,26% ) | 106 593 $ | 31.05.2024 |
Aktive Positionen von James Scibetta
Unternehmen | Position | Beginn |
---|---|---|
MATINAS BIOPHARMA HOLDINGS, INC. | Direktor/Vorstandsmitglied | 01.11.2013 |
Maverick Therapeutics, Inc.
![]() Maverick Therapeutics, Inc. BiotechnologyHealth Technology Maverick Therapeutics, Inc. operates as a preclinical stage biotech company. It develops a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism. The company was founded by Robert Dubridge and Patrick A. Baeuerle in 2016 and is headquartered in Brisbane, CA. | Vorstandsvorsitzender | 01.01.2017 |
ImmuneID, Inc.
![]() ImmuneID, Inc. Miscellaneous Commercial ServicesCommercial Services ImmuneID, Inc. is a precision immunology company that combines next-generation sequencing with protein display technologies to develop novel therapies for immune diseases. The company's proprietary platform identifies millions of antibody-target interactions to build the map of human immunity, which helps to improve and personalize patient diagnoses for precise treatments. The company was founded in 2020 by Longwood Fund and is headquartered in Boston, MA. James S. Scibetta has been the CEO of the company since 2021. | Vorstandsvorsitzender | 21.09.2021 |
Ehemalige bekannte Positionen von James Scibetta
Unternehmen | Position | Ende |
---|---|---|
AQUESTIVE THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 22.06.2022 |
PACIRA BIOSCIENCES, INC. | Finanzdirektor/CFO | 03.05.2016 |
NEPHROS, INC. | Vorsitzender | 31.12.2013 |
Labopharm, Inc.
![]() Labopharm, Inc. BiotechnologyHealth Technology Labopharm, Inc. discovers and develops drugs. The company was founded in 1990 and is headquartered in Montreal, Canada. | Direktor/Vorstandsmitglied | 07.11.2008 |
Bioenvision, Inc.
![]() Bioenvision, Inc. Medical/Nursing ServicesHealth Services Bioenvision, Inc. engages in the acquisition, development, distribution, and marketing of compounds and technologies for the treatment of cancer. It also develops anti-infective technologies, which includes the OLIGON(R) technology. The company was founded by Christopher B. Wood on August 16, 1996 and is headquartered in New York, NY. | Finanzdirektor/CFO | 01.11.2007 |
Ausbildung von James Scibetta
Wake Forest University | Undergraduate Degree |
University of Michigan | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 4 |
---|---|
NEPHROS, INC. | Health Technology |
PACIRA BIOSCIENCES, INC. | Health Technology |
MATINAS BIOPHARMA HOLDINGS, INC. | Health Technology |
AQUESTIVE THERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 5 |
---|---|
Labopharm, Inc.
![]() Labopharm, Inc. BiotechnologyHealth Technology Labopharm, Inc. discovers and develops drugs. The company was founded in 1990 and is headquartered in Montreal, Canada. | Health Technology |
Merrimack Pharmaceuticals, Inc.
![]() Merrimack Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Merrimack Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. engages in discovering, developing, and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer. Its pipeline includes MM-131, MM-141, and MM-310. The company was founded by Anthony J. Sinskey, Gavin MacBeath, and Ulrik B. Nielsen in 1993 and is headquartered in Cambridge, MA. | Health Technology |
Bioenvision, Inc.
![]() Bioenvision, Inc. Medical/Nursing ServicesHealth Services Bioenvision, Inc. engages in the acquisition, development, distribution, and marketing of compounds and technologies for the treatment of cancer. It also develops anti-infective technologies, which includes the OLIGON(R) technology. The company was founded by Christopher B. Wood on August 16, 1996 and is headquartered in New York, NY. | Health Services |
Maverick Therapeutics, Inc.
![]() Maverick Therapeutics, Inc. BiotechnologyHealth Technology Maverick Therapeutics, Inc. operates as a preclinical stage biotech company. It develops a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism. The company was founded by Robert Dubridge and Patrick A. Baeuerle in 2016 and is headquartered in Brisbane, CA. | Health Technology |
ImmuneID, Inc.
![]() ImmuneID, Inc. Miscellaneous Commercial ServicesCommercial Services ImmuneID, Inc. is a precision immunology company that combines next-generation sequencing with protein display technologies to develop novel therapies for immune diseases. The company's proprietary platform identifies millions of antibody-target interactions to build the map of human immunity, which helps to improve and personalize patient diagnoses for precise treatments. The company was founded in 2020 by Longwood Fund and is headquartered in Boston, MA. James S. Scibetta has been the CEO of the company since 2021. | Commercial Services |